PMV Pharmaceuticals, Inc. Logo

PMV Pharmaceuticals, Inc.

Developing small molecule therapies targeting p53 mutations to treat cancer.

PMVP | US

Overview

Corporate Details

ISIN(s):
US69353Y1038
LEI:
Country:
United States of America
Address:
400 ALEXANDER PARK DRIVE, 8540 PRINCETON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

PMV Pharmaceuticals, Inc. is a clinical-stage precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies for cancer. The company's research is dedicated to targeting mutations in the p53 tumor suppressor protein, which are found in approximately half of all human cancers. PMV's unique therapeutic approach aims to restore the normal tumor-suppressing function of mutated p53 by structurally correcting the protein's geometry. Its pipeline consists of first-in-class p53 regulators designed to provide new treatment options for patients whose tumors harbor these specific mutations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all PMV Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for PMV Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for PMV Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Legend Biotech Corp Logo
Develops and commercializes CAR-T cell therapies for cancer, including CARVYKTI® for myeloma.
United States of America
LEGN
LENZ Therapeutics, Inc. Logo
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America
LENZ
Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN

Talk to a Data Expert

Have a question? We'll get back to you promptly.